⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GPCR News
Structure Therapeutics Inc. American Depositary Shares
Form 8-K
sec.gov
GPCR
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
globenewswire.com
GPCR
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
globenewswire.com
GPCR
Form 8-K
sec.gov
GPCR
Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
globenewswire.com
GPCR
PatentVest Releases New Report on The Oral Small-Molecule GLP-1 Patent Race
globenewswire.com
MDBH
LLY
NVO
PFE
AZN
GILD
GPCR
Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
globenewswire.com
GPCR
Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional ADSs
globenewswire.com
GPCR
Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants
globenewswire.com
GPCR
Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants
globenewswire.com
GPCR